---
title: "Shanghai Kehua Bio-engineering CO.,LTD (002022.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002022.SZ.md"
symbol: "002022.SZ"
name: "Shanghai Kehua Bio-engineering CO.,LTD"
industry: "Biotechnology"
datetime: "2026-05-20T22:22:52.309Z"
locales:
  - [en](https://longbridge.com/en/quote/002022.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002022.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002022.SZ.md)
---

# Shanghai Kehua Bio-engineering CO.,LTD (002022.SZ)

## Company Overview

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemiluminescence immunoassay analyzers and CLIA reagents test menu; automatic ELISA microplate readers, ELISA microplate washers, and enzyme-linked immunoassay reagents; and diagnostics kit for HIV and SARS-CoV-2 IgM/IgG antibody, HIV I/II Ab rapid tests, diagnostic kit for Hepatitis B surface antigen and Hepatitis C virus antibody, and diagnostic kit for antibody to T. Palladium.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.skhb.com](https://www.skhb.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: D (0.62)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 80 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -3.17% |  |
| Net Profit YoY | -9.37% |  |
| P/B Ratio | 1.20 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3050372040.44 |  |
| Revenue | 1652633014.15 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -24.71% | E |
| Profit Margin | -44.09% | E |
| Gross Margin | 36.81% | B |
| Revenue YoY | -3.17% | D |
| Net Profit YoY | -9.37% | D |
| Total Assets YoY | -12.49% | E |
| Net Assets YoY | -22.52% | E |
| Cash Flow Margin | 3.94% | D |
| OCF YoY | -3.17% | D |
| Turnover | 0.34 | D |
| Gearing Ratio | 32.90% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Kehua Bio-engineering CO.,LTD",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-3.17%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-9.37%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.20",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3050372040.44",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1652633014.15",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-24.71%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-44.09%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "36.81%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-3.17%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-9.37%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-12.49%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-22.52%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "3.94%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-3.17%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.34",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "32.90%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.17 | 47/81 | - | - | - |
| PB | 1.20 | 6/81 | 1.12 | 1.03 | 0.99 |
| PS (TTM) | 1.84 | 1/81 | 2.11 | 1.98 | 1.86 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002022.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002022.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002022.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002022.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**